GlassScriptPhysician profile
Abraham P Chacko
NPI 1902117773
$5,333.82
in general payments reported to CMS, 2019-2025
36 companies · $879 in 2025
The $879 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $394 · 2021: $608 · 2022: $619 · 2023: $798 · 2024: $913 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $1,072.83 | 2019-2020 | |
| Abbvie INC. | $690.08 | 2019-2025 | Linzess, Viberzi, Creon |
| Medtronic, INC. | $590.84 | 2021-2025 | Endoflip, Barrx |
| Endogastric Solutions, INC | $510.18 | 2022-2024 | Esophyx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.25 | 2019-2025 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $294.17 | 2019-2025 | Entyvio, Eohilia |
| Axonics, INC. | $277.29 | 2023-2024 | Axonics |
| Phathom Pharmaceuticals, INC. | $225.31 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $190.09 | 2024-2025 | Omvoh |
| Anx Robotica Corp | $126.83 | 2024 | |
| Janssen Biotech, INC. | $100.91 | 2019-2025 | Tremfya, Stelara, Remicade |
| Boston Scientific Corporation | $93.48 | 2020-2022 | |
| Intuitive Surgical, INC. | $92.21 | 2023 | Da Vinci Surgical System |
| Steris Corporation | $90.13 | 2021 | |
| Gilead Sciences, INC. | $86.50 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $64.62 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $57.43 | 2020-2022 | |
| Conmed Corporation | $53.71 | 2019-2024 | Conmed Biliary, Conmed Generators |
| Nestle Healthcare Nutrition INC. | $52.97 | 2022 | |
| Aimmune Therapeutics, INC. | $52.18 | 2024-2025 | Zenpep |
| Lundbeck LLC | $30.10 | 2024 | Vyepti |
| Vivus LLC | $24.07 | 2023 | Qsymia |
| Qol Medical, LLC | $23.91 | 2025 | Sucraid |
| Ardelyx, INC. | $23.20 | 2023 | Ibsrela |
| Genzyme Corporation | $22.53 | 2023 | |
| Corcept Therapeutics | $21.36 | 2024 | Korlym |
| Grifols USA, LLC | $19.53 | 2025 | Gamunex-C |
| Pfizer INC. | $19.23 | 2025 | |
| Harmony Biosciences LLC | $18.64 | 2024 | |
| Celltrion USA INC. | $17.51 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $16.62 | 2021 | |
| Evoke Pharma, INC. | $15.56 | 2024 | |
| Ucb, INC. | $15.17 | 2025 | Rystiggo |
| Endo Pharmaceuticals INC. | $13.46 | 2019 | |
| Celgene Corporation | $12.78 | 2023 | Zeposia |
| Shire North American Group INC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Chacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.